Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2026 | 1 | -$0.02 | -$0.02 | -$0.02 |
| Q2 2026 | 1 | -$0.02 | -$0.02 | -$0.02 |
| Q3 2026 | 1 | -$0.02 | -$0.02 | -$0.02 |
| Q4 2026 | 1 | -$0.02 | -$0.02 | -$0.02 |
| Q1 2027 | 1 | -$0.02 | -$0.02 | -$0.02 |
| Q2 2027 | 1 | -$0.02 | -$0.02 | -$0.02 |
| Q3 2027 | 1 | -$0.02 | -$0.02 | -$0.02 |
| Q4 2027 | 1 | -$0.02 | -$0.02 | -$0.02 |
IGC Pharma Inc last posted its earnings results on Friday, June 26th, 2026. The company reported $-0.02 earnings per share for the quarter, missing analysts' consensus estimates of $-0.02 by $0. The company had revenue of 317.00 K for the quarter and had revenue of 1.19 M for the year. IGC Pharma Inc has generated $0 earnings per share over the last year ($-0.0723 diluted earnings per share) and currently has a price-to-earnings ratio of -3.64. IGC Pharma Inc has not formally confirmed its next earnings publication date, but the company's estimated earnings date is N/A based on prior year's report dates.
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 05/15/2026 | Q4 2026 | N/A | -$0.03 | N/A | $198.00 K | $317.00 K |
| 12/30/2025 | Q3 2026 | N/A | -$0.01 | N/A | $198.00 K | $350.00 K |
| 11/14/2025 | Q2 2026 | -$0.02 | -$0.02 | -0 | $383.00 K | $191.00 K |
| 08/14/2025 | Q1 2026 | N/A | -$0.02 | N/A | $305.00 K | $328.00 K |
| 06/27/2025 | Q4 2025 | N/A | -$0.02 | N/A | $204.00 K | $330.00 K |
| 02/14/2025 | Q3 2025 | N/A | -$0.02 | N/A | $291.00 K | $257.00 K |
| 11/12/2024 | Q2 2025 | N/A | -$0.02 | N/A | $450.00 K | $412.00 K |
| 08/07/2024 | Q1 2025 | N/A | -$0.03 | N/A | $193.00 K | $272.00 K |
| 06/24/2024 | Q4 2024 | -$0.00 | -$0.04 | -0.04 | $193.00 K | $295.00 K |
| 02/14/2024 | Q3 2024 | -$0.04 | -$0.09 | -0.05 | N/A | $204.00 K |
| 11/09/2023 | Q2 2024 | N/A | -$0.05 | N/A | N/A | $291.00 K |
| 08/10/2023 | Q1 2024 | N/A | -$0.04 | N/A | N/A | $555.00 K |
| 07/07/2023 | Q4 2023 | N/A | -$0.08 | N/A | N/A | $166.00 K |
| 02/14/2023 | Q3 2023 | N/A | -$0.04 | N/A | N/A | $332.00 K |
| 11/01/2022 | Q2 2023 | N/A | -$0.05 | N/A | N/A | $202.00 K |
| 08/05/2022 | Q1 2023 | N/A | -$0.05 | N/A | N/A | $212.00 K |
| 06/22/2022 | Q4 2022 | N/A | -$0.15 | N/A | N/A | $122.00 K |
| 02/10/2022 | Q3 2022 | N/A | -$0.05 | N/A | N/A | $142.00 K |
| 10/29/2021 | Q2 2022 | N/A | -$0.09 | N/A | N/A | $56.00 K |
| 08/11/2021 | Q1 2022 | N/A | -$0.04 | N/A | N/A | $77.00 K |
The conference call for IGC Pharma Inc's latest earnings report can be listened to online.
The conference call transcript for IGC Pharma Inc's latest earnings report can be read online.
IGC Pharma Inc (:IGC) has a recorded annual revenue of $1.19 M.
IGC Pharma Inc (:IGC) has a recorded net income of $-6,548,000.IGC Pharma Inc has generated $-0.0723 earnings per share over the last four quarters.
IGC Pharma Inc (:IGC) has a price-to-earnings ratio of -3.64 and price/earnings-to-growth ratio is -0.18.
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED